CN102698116A - Application of lophatherum gracile total flavonoids in preparation of medicine and functional food for preventing and treating myocardial ischemia disease - Google Patents
Application of lophatherum gracile total flavonoids in preparation of medicine and functional food for preventing and treating myocardial ischemia disease Download PDFInfo
- Publication number
- CN102698116A CN102698116A CN2012102260413A CN201210226041A CN102698116A CN 102698116 A CN102698116 A CN 102698116A CN 2012102260413 A CN2012102260413 A CN 2012102260413A CN 201210226041 A CN201210226041 A CN 201210226041A CN 102698116 A CN102698116 A CN 102698116A
- Authority
- CN
- China
- Prior art keywords
- herba lophatheri
- total flavones
- myocardial ischemia
- medicine
- functional food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of lophatherum gracile total flavonoids in preparation of medicine and functional food for preventing and treating myocardial ischemia disease. Shown by the experiment results, the lophatherum gracile total flavonoids are safe without toxic or side effect, and have obvious inhibiting effect on ear swelling model caused by p-dimethylbenzene, can inhibit platelet aggregation and prolong the thrombosis time, and have better protection effect on rat myocardial ischemia and myocardial ischemia reperfusion injury caused by pituitrin. Furthermore, shown by screening results of a great amount of experiments, after being combined with antiplatelet aggregation medication, beta-receptor blocking pharmacon, calcium ion antagonist, statins, RAS system blocking agent, nitrite medication and thrombolysis medication or angiotensin-converting enzyme inhibitor, the the lophatherum gracile total flavonoids show better antiplatelet aggregation, is capable of prolonging the thrombosis time, have better protection effect on rat myocardial ischemia and myocardial ischemia reperfusion injury caused by pituitrin, and play a better synergistic effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine extract, be specifically related to the Herba Lophatheri total flavones in the medicine of preparation control myocardial ischemia disease and the application in the functional food.
Background technology
In recent years along with growth in the living standard, the health of myocardial ischemia serious harm middle-aged and elderly people, coronary atherosclerosis presents the trend of rejuvenation, and the performance of myocardial ischemia also appears in some youngsters.
Cardiovascular disease is called blood circulation diseases again, and blood circulation refers to hemophoric organ and tissue in the human body, mainly comprises heart and blood vessel, can be subdivided into acute and chronic, generally all relevant with arteriosclerosis.
Myocardial ischemia is meant that the hemoperfusion of heart reduces, and causes the oxygen-supplying amount of heart to reduce, and energy metabolism of myocardial is undesired, can not support a kind of pathological state of heart operate as normal.The coronary stenosis that coronary atherosclerosis causes is to cause main, the modal cause of disease of myocardial ischemia, and then causes myocardial ischemia-anoxemia, so coronary heart disease is the main cause of myocardial ischemia.Myocardial ischemia mainly is divided into 5 types of latent coronary heart disease, angina pectoris, myocardial infarction type, ischemic cardiomyopathy and sudden death property.
The common reason of myocardial ischemia is a coronary atherosclerosis, secondly also has inflammation (rheumatic, syphilis property, mucocutaneous lymphnode syndrome and thromboangitis obliterans etc.), spasm, thromboembolism, connective tissue disease, wound and congenital malformation etc. multiple.Epidemiological study finds, the significant risk factor relevant with atherosclerosis is that hyperlipemia, hypertension, diabetes, smoking, obesity, homocysteine increase, physical exertion is few, advanced age and male etc.The damage mechanism of ischemic myocardium comprise energy deficiency, calcium overload, free radical generate increase, aspects such as cardiac damage that acidosis causes, permeability of cell membrane increase.
Flavone compound extensively exists in natural plant and the fruit, and modern pharmacological research shows that flavone compound has multiple biological activity; Comprise cardiovascular system activity; Antibiotic and antiviral activity, anti-tumor activity, resisting oxidation free radical is active; Antiinflammatory, analgesic activities, liver-protecting activity, blood pressure lowering, blood fat reducing, defying age, human body immunity improving power, rush down down, antitussive, eliminate the phlegm, pharmacologically actives such as spasmolytic and resistance attitude.
Herba Lophatheri is the dry stem and leaf of grass Herba Lophatheri; The Herba Lophatheri extractive of general flavone is a kind of plant flavonoids preparation of Nanjing University of Traditional Chinese Medicine's exploitation, and " a kind of method for preparing CN101797344A of Herba Lophatheri refined total flavonoids discloses a kind of preparation process for purification of Herba Lophatheri total flavones to its patent of invention.But up to now, still there is not the Herba Lophatheri total flavones to the physiology of myocardial ischemia disease and the research report of pharmacologically active.
Therefore in order to make full use of resource, meet the need of market a kind of medicine of necessary research and development with fine control myocardial ischemia disease.
Summary of the invention:
Goal of the invention: the objective of the invention is in order to solve the deficiency of prior art,, provide the Herba Lophatheri total flavones to prevent and treat the medicine of myocardial ischemia disease and the application in the functional food in preparation through a large amount of experiment screenings.
Technical scheme: in order to realize above purpose, the present invention adopts following technical scheme:
The Herba Lophatheri total flavones is in the medicine of preparation control myocardial ischemia disease and the application in the functional food, and described Herba Lophatheri total flavones is prepared by following method:
(1) get fresh Herba Lophatheri, clean, put into extraction pot after the drying, add the water of 5～10 times of amounts, reflux 1～3 time is filtered, merge extractive liquid,, concentrate, the water extract of Herba Lophatheri is subsequent use;
(2) get Herba Lophatheri water extract that step (1) obtains and add ethanol and make that concentration of ethanol reaches 65%～75% in the Herba Lophatheri water extract, leave standstill, precipitate, leach solution, concentrate, the alcohol deposit fluid of Herba Lophatheri water extract is for use;
(3) get macroporous resin column on the Herba Lophatheri alcohol deposit fluid that step (2) obtains; Water and concentration are 10% ethanol elution respectively earlier; Reuse concentration is 50%～55% ethanol elution, and thin layer chromatography inspection is known, collected 50%～55% ethanol elution, concentrates, drying under reduced pressure obtains the Herba Lophatheri total flavones.
As preferred version; Above-described Herba Lophatheri total flavones is in the medicine of preparation control myocardial ischemia disease and the application in the functional food, and described Herba Lophatheri total flavones comprises orientin, Lutonaretin, swertiajaponin, swertisin, apigenin-8-C-glucoside, Saponaretin, luteoloside and tricin.
Flavones content is high in the Herba Lophatheri total flavones provided by the invention, has flavone such as orientin, Lutonaretin, swertiajaponin, swertisin, apigenin-8-C-glucoside, Saponaretin, luteoloside and tricin, and content is up to 50 to 90%.Experimental result shows the effect with good resisting myocardial ischemia.
The compositions of Herba Lophatheri total flavones and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug, angiotensin converting enzyme inhibitor or Radix Salviae Miltiorrhizae Injection is in the medicine of preparation control myocardial ischemia disease and the application in the functional food, and described Herba Lophatheri total flavones is prepared by following method:
(1) get fresh Herba Lophatheri, clean, put into extraction pot after the drying, add the water of 5～10 times of amounts, reflux 1～3 time is filtered, merge extractive liquid,, concentrate, the water extract of Herba Lophatheri is subsequent use;
(2) get Herba Lophatheri water extract that step (1) obtains and add ethanol and make that concentration of ethanol reaches 65%～75% in the Herba Lophatheri water extract, leave standstill, precipitate, leach solution, concentrate, the alcohol deposit fluid of Herba Lophatheri water extract is for use;
(3) get macroporous resin column on the Herba Lophatheri alcohol deposit fluid that step (2) obtains; Water and concentration are 10% ethanol elution respectively earlier; Reuse concentration is 50%～55% ethanol elution, and thin layer chromatography inspection is known, collected 50%～55% ethanol elution, concentrates, drying under reduced pressure obtains the Herba Lophatheri total flavones.
As preferred version; The compositions of above-described Herba Lophatheri total flavones and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug, angiotensin converting enzyme inhibitor or Radix Salviae Miltiorrhizae Injection is in the medicine of preparation control myocardial ischemia disease and the application in the functional food, and described Herba Lophatheri total flavones comprises orientin, Lutonaretin, swertiajaponin, swertisin, apigenin-8-C-glucoside, Saponaretin, luteoloside and tricin.
The Herba Lophatheri total flavones has effects such as good antithrombotic, antiplatelet aggregation; The present invention is on the basis of Herba Lophatheri total flavones; Through a large amount of experiment screening combinations; Experimental result shows after Herba Lophatheri total flavones and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug, angiotensin converting enzyme inhibitor or the Radix Salviae Miltiorrhizae Injection combination, to have the effect of better anti-cardiovascular disease.
As preferred version, above-described medicament for resisting platelet aggregation can be aspirin, receptor blocking agent and can be Propranolol, calcium ion antagonist and can be verapamil etc., statins, the agent of RAS system blocking, nitric acid lipid drug and can be nitric acid ground equality.
As preferred version, the application of compositions in preventing and treating cardiovascular disease such as coronary heart disease, latent coronary heart disease, angina pectoris, myocardial infarction or ischemic cardiomyopathy of Herba Lophatheri total flavones provided by the invention or Herba Lophatheri total flavones and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug, angiotensin converting enzyme inhibitor or Radix Salviae Miltiorrhizae Injection.
Herba Lophatheri total flavones provided by the invention can be processed the medicine of dosage forms such as decoction, oral liquid, electuary, syrup, tablet, capsule, granule, powder, pill, drop pill, unguentum with pharmaceutically acceptable carrier.
When processing tablet,, add magnesium stearate lubricant when needing Herba Lophatheri total flavones and carrier lactose or corn starch, mix homogeneously, tabletting is processed tablet then.When processing capsule Herba Lophatheri total flavones and carrier lactose or corn starch mix homogeneously, granulate, the encapsulated then capsule of processing.When processing granule, Herba Lophatheri total flavones and diluent lactose or corn starch mix homogeneously, granulate, drying is processed granule.
Beneficial effect: the present invention compared with prior art has the following advantages:
(1) Herba Lophatheri total flavones provided by the invention prepares through selection process, and it is many to contain the flavone kind, and purity is high, and experimental result shows that Herba Lophatheri total flavones safety non-toxic has no side effect, and the ear swelling model has the obvious suppression effect due to the xylol; But anticoagulant prolongs TFT; Rat heart muscle ischemia due to the pituitrin and rat myocardial ischemia and reperfusion damage there is the better protect effect.
(2) the present invention is the basis with the Herba Lophatheri total flavones that selection process prepares; Through a large amount of experiment screenings; Demonstrated good antiplatelet aggregation after Herba Lophatheri total flavones and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug or the angiotensin converting enzyme inhibitor combination; Prolong TFT, and rat heart muscle ischemia due to the pituitrin damaged with rat myocardial ischemia and reperfusion the better protection effect is arranged, played Synergistic effect preferably; Thereby clinically can reduce drug dose; Reduce untoward reaction, more scientific medication has the better application prospect.
The specific embodiment
According to following embodiment, can understand the present invention better.Yet, those skilled in the art will readily understand that the described concrete material proportion of embodiment, process conditions and result thereof only are used to explain the present invention, and the present invention that should also can not limit in claims to be described in detail.
Embodiment 1
A kind of Herba Lophatheri total flavones, it is to prepare through following method:
(1) get fresh Herba Lophatheri, clean, put into extraction pot after the drying, add the water of 10 times of amounts, reflux 3 times is filtered, merge extractive liquid,, concentrate, the water extract of Herba Lophatheri is subsequent use;
(2) get Herba Lophatheri water extract that step (1) obtains and add ethanol and make that concentration of ethanol reaches 65%～75% in the Herba Lophatheri water extract, leave standstill, precipitate, leach solution, concentrate, the alcohol deposit fluid of Herba Lophatheri water extract is for use;
(3) get macroporous resin column on the Herba Lophatheri alcohol deposit fluid that step (2) obtains; Water and concentration are 10% ethanol elution respectively earlier; Reuse concentration is 50%～55% ethanol elution, and thin layer chromatography inspection is known, collected 50%～55% ethanol elution, concentrates, drying under reduced pressure obtains the Herba Lophatheri total flavones.Show through high performance liquid chromatogram and the detection of mass spectrum technology used in conjunction, contain orientin, Lutonaretin, swertiajaponin, swertisin, apigenin-8-C-glucoside, Saponaretin, luteoloside and tricin in the Herba Lophatheri total flavones.
Embodiment 2 acute toxicity testings and maximum dosage-feeding are measured
The maximum dosage-feeding result of the test of the Herba Lophatheri total flavones gastric infusion that embodiment 1 prepares shows: equal non-toxic reaction after 20 mice administrations, main histoorgan does not all have tangible change, does not have dead in 7 days.The mice maximum dosage-feeding of Herba Lophatheri total flavones gastric infusion is 14.14gkg
-1, this dosage is equivalent to 176.8 times of the maximum dosage of pharmacodynamics.Showing that Herba Lophatheri total flavones provided by the invention separates from natural Herba Lophatheri obtains, and toxicity is low, and safety is good.
The experiment of embodiment 3 antiinflammatories
Get 50 of female mices, body weight (20 ± 3) g is provided by Nanjing University of Traditional Chinese Medicine zoopery center.
Be divided into high, medium and low totally 5 groups of the Herba Lophatheri total flavones that blank group, xylene group, embodiment 1 prepare at random, 10 every group.The continuous gastric infusion of administration treated animal 7 days, the blank group gives isometric normal saline.Behind the last administration 1h, the two sides is coated with the xylene of 25 μ l before and after the auris dextra of every mice, after the 2h, with sacrifice of animal, lays round auricle at the same position of ears respectively with 8mm diameter card punch, and analytical balance is weighed.The auris dextra sheet weight of every Mus deducts left auricle and heavily is the swelling degree.Compare with blank group and xylene model group, concrete experimental result is as shown in table 1.
The influence
of table 1 Herba Lophatheri total flavones xylol induced mice ear swelling degree
Annotate: compare with the blank group,
##P＜0.01; * P＜0.05 of comparing with the xylene group, * * P＜0.01.
Experimental result shows: Herba Lophatheri total flavones provided by the invention 80,40,20mg.kg
-1Dose groups can effectively alleviate xylene induced mice ear swelling degree in various degree, with 80mgkg
-1Dose groups changes the most obviously (P＜0.01).The Herba Lophatheri total flavones has tangible anti-inflammatory activity, and is good dose dependent.The antiinflammatory action of Herba Lophatheri total flavones has a better role for the inflammatory reaction tool of ischemic heart desease.
4 pairs of antiplatelet aggregation of embodiment and thrombotic influence
4.1 the Herba Lophatheri total flavones is to the influence of TFT
Get 50 of female rats, body weight (200 ± 3) g is divided into 5 groups at random, i.e. the Herba Lophatheri total flavones group 80mgkg for preparing of blank group, aspirin group, the embodiment of the invention 1
-1And 40mgkg
-1, Herba Lophatheri total flavones that the embodiment of the invention 1 prepares and aspirin group (30mgkg
-1+ 10 mgkg
-)
1Group, 10 every group.The continuous gastric infusion of each administration treated animal 7 days, the blank group gives isometric normal saline.Behind the last administration 1h, experimental rat is with 10% chloral hydrate solution (350mgkg
-1) anesthesia, face upward the position and fix, separate left carotid, the thrombosis detector stimulating electrode is put in the common carotid artery proximal part; Thermosensitive thermometer is put in distal end, opens instrument switch, and 7min pushes 0 position with ammeter pointer with the 2mA galvanism; When blood flow was blocked fully, temperature descended suddenly, reported to the police automatically together; Show duration of congestion, be TFT, concrete experimental result is as shown in table 2.After experiment finished, each organized rat extracting blood, centrifugal results serum, and-20 ℃ of preservations are to be checked.
Table 2 Herba Lophatheri total flavones is to the influence
of rat suppository formation time
Annotate: compare * P＜0.05**P＜0.01 with the blank group
Experimental result by table 2 shows: compare aspirin group, Herba Lophatheri total flavones 80,40mgkg with the blank group
-1The TFT of dose groups obviously prolongs (P＜0.05), shows the TFT that the Herba Lophatheri total flavones can prolong rats, and Herba Lophatheri total flavones and aspirin group 30+10mgkg
-1Compare with one Herba Lophatheri total flavones with one aspirin, demonstrated better antithrombotic effect, show that the two scientific combination has played good synergism.
4.2 the Herba Lophatheri total flavones is to the influence of rat blood serum PF4 content
Get 4.1 respectively organize rat serum, measure the level of PF4 with the ELISA method, concrete experimental result is as shown in table 3:
Table 3 Herba Lophatheri total flavones is to the influence
of rat blood serum PF4 content
Annotate: compare * P＜0.05**P＜0.01 with the blank group
Show by table 3 result: compare with the blank group; Herba Lophatheri total flavones and Herba Lophatheri total flavones thereof and aspirin group can obviously reduce PF4 content (P＜0.05 in the rat blood serum; 0.01), point out it can pass through to regulate blood-serum P F4 level affects platelet aggregation, and have the experiment comparing result to show; After Herba Lophatheri total flavones and the aspirin combination, demonstrated than one aspirin and the more superior effect of one Herba Lophatheri total flavones.
4.3 the Herba Lophatheri total flavones is to the influence of the inductive platelet aggregation maximum agglutination rate of ADP.
Get male rabbit, get blood, add 3.8% sodium citrate anticoagulant, 800 rev/mins of low-speed centrifugals.With PPP zeroing, be the platelet donor with PRP, experiment is respectively the blank group, and the present invention implements the 1 Herba Lophatheri total flavones final concentration 8,4,2,1, the 0.5mgml that prepare
-1, Radix Salviae Miltiorrhizae Injection group (being the original content of Radix Salviae Miltiorrhizae Injection), Herba Lophatheri total flavones+Radix Salviae Miltiorrhizae Injection group, 6 every group parallel appearance.Get 250 μ lPRP respectively, mix with the Herba Lophatheri total flavones solution of 10 μ l variable concentrations, behind 37 ℃ of incubation 3min; The ADP20 μ l that adds 20 μ mol/1 respectively; Measure platelet aggregation rate with platelet aggregation and blood clotting analyzer, and calculate suppression ratio, concrete experimental result is as shown in table 4.
Table 4 Herba Lophatheri total flavones is to the influence
of the inductive platelet aggregation maximum agglutination rate of ADP
Annotate: * * p＜0.01, compare with the blank group
Show by the experimental result of table 4, Herba Lophatheri total flavones provided by the invention 8,4,2,1mgml
-1The maximum agglutination rate of dose groups is respectively 10.11%, 10.7%, 11.55%, 14.63%; Suppression ratio is respectively 59.75%, 57.4%, 54.02%, 41.76%, 18.19%; Demonstrated the effect of good antiplatelet aggregation; And experimental result shows, Herba Lophatheri total flavones+Radix Salviae Miltiorrhizae Injection 8,4,2,1mgml
-1The suppression ratio of dose groups is 74.29%, 72.32%, 57.02% respectively, 49.76.76% and 20.19%; Show more superior antiplatelet aggregative activity; Also demonstrate synergistic function preferably after showing Herba Lophatheri total flavones+Radix Salviae Miltiorrhizae Injection combination, obtained good technical effect.
4.4 the Herba Lophatheri total flavones is to the influence of each time point PAR of the inductive platelet aggregation of ADP.
The platelet aggregation rate of record different time points calculates PAR, and concrete experimental result is as shown in table 5.
Table 5 Herba Lophatheri total flavones is to the influence
of each time point PAR of the inductive platelet aggregation of ADP
Annotate: * P＜0.05, compare with the blank group * * P＜0.01
Experimental result by table 5 shows; Herba Lophatheri total flavones provided by the invention has the effect of good restraining platelet aggregation; And show by experimental result; Herba Lophatheri total flavones+Radix Salviae Miltiorrhizae Injection provided by the invention has the effect of more superior antiplatelet aggregation, show the two scientific combination after, have good synergistic effects.
The influence of 5 pairs of rat heart muscle ischemia models of embodiment
5.1 influence to rat heart muscle ischemia model due to the pituitrin
Laboratory animal is divided following group at random, i.e. blank group, pituitrin model group, nifedipine positive controls (4.5mgkg
-1), the present invention implements 1 and prepares Herba Lophatheri total flavones 80mgkg
-1, 40mgkg
-1And 20mgkg
-1Dose groups is implemented 1 and is prepared Herba Lophatheri total flavones and N group 40+40mgkg
-1, 20+20mgkg
-1And 10mgkg
-1Dose groups, 10 every group.The continuous gastric infusion of drug group animal 7 days, blank group, pituitrin model group give isometric normal saline.Behind the last administration 1h, appoint for every group and get 8 animals, with 10% chloral hydrate 350mgkg
-1The intraperitoneal injection of anesthesia animal, it is fixing to face upward the position, and it is subcutaneous that electrocardioelectrode is inserted extremity, the record II normal ECG that leads.After treating that electrocardiogram is stable, by sublingual vein injection of pituitrin 0.5Ukg
-1(2mlkg
-1), the time was controlled at 15 seconds, and the normal saline of normal control group injection same amount is gathered electrocardiogram, continuous record 15 minutes immediately.
5.2 injection of pituitrin rat T ripple is changed
Before measuring injection of pituitrin respectively, 5 seconds, 10 seconds, 15 seconds, 30 seconds, 1 minute, 5 minutes, 10 minutes, 15 minutes ECG T wave height change of totally 9 time points (being Δ T), each time point is got 10 waveforms continuously, averages.Before the injection of pituitrin T wave height meansigma methods respectively with the absolute value of the difference of all the other each time point T wave height, be each time point T ripple amplitude of variation.
Table 6 Herba Lophatheri total flavones causes the influence
that rat heart muscle ischemia T ripple changes to pituitrin
Annotate: compare with blank control group: * P＜0.05, * * P＜0.01; Compare with model group:
#P＜0.05,
##P＜0.01
Shown by table 6 experimental result: obvious T ripple change appears in 5s behind the blank group rat injection of pituitrin, and the persistent period is longer; And each dose groups T ripple change time of occurrence of Herba Lophatheri total flavones is shorter; And the change amplitude is not obvious; Show that the Herba Lophatheri total flavones has the certain protection effect to ischemic myocardium, and also demonstrated the effect that has demonstrated the better protection myocardial ischemia than single Herba Lophatheri total flavones after Herba Lophatheri total flavones+nifedipine combination.
5.3 SOD in serum, MDA content detection
Get injection of pituitrin and respectively organized the serum of rat in 15 minutes, with MDA and SOD in the kit measurement serum.
Table 7 Herba Lophatheri total flavones is to the influence
of rat blood serum MDA, SOD content
Annotate: compare with the blank group,
#P＜0.05; Compare * P＜0.05 with model group
Experimental result by table 7 shows: compare with model group; Herba Lophatheri total flavones high dose group can obviously reduce Content of MDA; Rising SOD in serum level; And more single Herba Lophatheri total flavones demonstrated more superior reduction Content of MDA after Herba Lophatheri total flavones+nifedipine combination, and rising SOD in serum level is effect, illustrates the effect of Herba Lophatheri total flavones provided by the invention or Herba Lophatheri total flavones+nifedipine protection myocardial ischemia from molecular level.
5.4 protective effect to the rat myocardial ischemia and reperfusion damage
Laboratory animal is divided into model group at random, sham operated rats, TONGXINLUO JIAONANG group (100mgkg
-1), Herba Lophatheri total flavones 100mgkg
-1, 50mgkg
-1, 25mgkg
-1Dose groups, 8 every group.Gastric infusion, continuous 10 days.Sham operated rats and model group are irritated stomach respectively and are given corresponding volumetrical normal saline.Sham operated rats is identical with the surgical groups operation, but the ligation that do not operate.Set up the rat myocardial ischemia and reperfusion model, behind the ligation arteria coronaria left anterior descending branch 30min, pour into 24h again after, common carotid artery is got blood, centrifugal blood removes supernatant, it is frozen subsequent use to put-20 ℃ of refrigerators, concrete experimental result is as shown in table 8.
Table 8 Herba Lophatheri total flavones to ischemia-reperfusion after rat blood serum influence
Annotate: compare with sham operated rats:
#P＜0.05,
##P＜0.01; Compare with model group:
*P＜0.05,
*P＜0.01
Experimental result by table 8 shows; Herba Lophatheri total flavones provided by the invention can obviously suppress spilling of LDH and CK in the rat heart muscle; Reduce LDH and CK activity in serum and the cardiac muscular tissue; Reduce MDA content, improve SOD, GSH-PX and NO concentration, show that the Herba Lophatheri total flavones has good protective effect to the myocardial damage of Ischemia and Reperfusion in vivo in Rats.
The above only is a preferred implementation of the present invention; Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention; Can also make some improvement and retouching, these improvement and retouching also should be regarded as protection scope of the present invention.
Claims (7)
1. the Herba Lophatheri total flavones is in the medicine of preparation control myocardial ischemia disease and the application in the functional food, and described Herba Lophatheri total flavones is prepared by following method:
(1) get fresh Herba Lophatheri, clean, put into extraction pot after the drying, add the water of 5～10 times of amounts, reflux 1～3 time is filtered, merge extractive liquid,, concentrate, the water extract of Herba Lophatheri is subsequent use;
(2) get Herba Lophatheri water extract that step (1) obtains and add ethanol and make that concentration of ethanol reaches 65%～75% in the Herba Lophatheri water extract, leave standstill, precipitate, leach solution, concentrate, the alcohol deposit fluid of Herba Lophatheri water extract is for use;
(3) get macroporous resin column on the Herba Lophatheri alcohol deposit fluid that step (2) obtains; Water and concentration are 10% ethanol elution respectively earlier; Reuse concentration is 50%～55% ethanol elution, and thin layer chromatography inspection is known, collected 50%～55% ethanol elution, concentrates, drying under reduced pressure obtains the Herba Lophatheri total flavones.
2. Herba Lophatheri total flavones according to claim 1 is in the medicine of preparation control myocardial ischemia disease and the application in the functional food; It is characterized in that described Herba Lophatheri total flavones comprises orientin, Lutonaretin, swertiajaponin, swertisin, apigenin-8-C-glucoside, Saponaretin, luteoloside and tricin.
3. the compositions of Herba Lophatheri total flavones and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug, angiotensin converting enzyme inhibitor or Radix Salviae Miltiorrhizae Injection is in the medicine of preparation control myocardial ischemia disease and the application in the functional food, and described Herba Lophatheri total flavones is prepared by following method:
(1) get fresh Herba Lophatheri, clean, put into extraction pot after the drying, add the water of 5～10 times of amounts, reflux 1～3 time is filtered, merge extractive liquid,, concentrate, the water extract of Herba Lophatheri is subsequent use;
(2) get Herba Lophatheri water extract that step (1) obtains and add ethanol and make that concentration of ethanol reaches 65%～75% in the Herba Lophatheri water extract, leave standstill, precipitate, leach solution, concentrate, the alcohol deposit fluid of Herba Lophatheri water extract is for use;
(3) get macroporous resin column on the Herba Lophatheri alcohol deposit fluid that step (2) obtains; Water and concentration are 10% ethanol elution respectively earlier; Reuse concentration is 50%～55% ethanol elution, and thin layer chromatography inspection is known, collected 50%～55% ethanol elution, concentrates, drying under reduced pressure obtains the Herba Lophatheri total flavones.
4. the compositions of Herba Lophatheri total flavones according to claim 3 and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug, angiotensin converting enzyme inhibitor or Radix Salviae Miltiorrhizae Injection is in the medicine of preparation control myocardial ischemia disease and the application in the functional food; It is characterized in that described Herba Lophatheri total flavones comprises orientin, Lutonaretin, swertiajaponin, swertisin, apigenin-8-C-glucoside, Saponaretin, luteoloside and tricin.
5. the compositions of Herba Lophatheri total flavones according to claim 3 and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug or angiotensin converting enzyme inhibitor or Radix Salviae Miltiorrhizae Injection is in the medicine of preparation control myocardial ischemia disease and the application in the functional food; It is characterized in that described medicament for resisting platelet aggregation is that aspirin, nitric acid lipid drug are the nitric acid Horizon.
6. Herba Lophatheri total flavones according to claim 1 is in the medicine of preparation control myocardial ischemia disease and the application in the functional food; It is characterized in that described myocardial ischemia disease is coronary heart disease, latent coronary heart disease, angina pectoris, myocardial infarction or ischemic cardiomyopathy.
7. prevent and treat the medicine of myocardial ischemia disease and the application in the functional food according to the compositions of claim 3 or 4 described Herba Lophatheri total flavones and medicament for resisting platelet aggregation, receptor blocking agent, calcium ion antagonist, statins, the agent of RAS system blocking, nitric acid lipid drug, thrombolytic drug, angiotensin converting enzyme inhibitor or Radix Salviae Miltiorrhizae Injection in preparation; It is characterized in that described myocardial ischemia disease is coronary heart disease, latent coronary heart disease, angina pectoris, myocardial infarction or ischemic cardiomyopathy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210226041.3A CN102698116B (en) | 2012-07-03 | 2012-07-03 | Application of lophatherum gracile total flavonoids in preparation of medicine and functional food for preventing and treating myocardial ischemia disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210226041.3A CN102698116B (en) | 2012-07-03 | 2012-07-03 | Application of lophatherum gracile total flavonoids in preparation of medicine and functional food for preventing and treating myocardial ischemia disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102698116A true CN102698116A (en) | 2012-10-03 |
| CN102698116B CN102698116B (en) | 2014-06-04 |
Family
ID=46891363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210226041.3A Active CN102698116B (en) | 2012-07-03 | 2012-07-03 | Application of lophatherum gracile total flavonoids in preparation of medicine and functional food for preventing and treating myocardial ischemia disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102698116B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287499A (en) * | 2015-10-09 | 2016-02-03 | 成都普瑞法科技开发有限公司 | Natural pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular diseases and application of pharmaceutical composition |
| CN105738553A (en) * | 2016-02-05 | 2016-07-06 | 四川德成动物保健品有限公司 | Thin-layer chromatography detection method for lophatherum gracile in scourge-clearing toxin-vanquishing powder |
| CN112587621A (en) * | 2020-12-18 | 2021-04-02 | 江西中医药大学 | Medicine for resisting myocardial ischemic diseases and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766274A (en) * | 2010-01-05 | 2010-07-07 | 杭州尤美特科技有限公司 | Antioxidant functional food composition containing bamboo-leaves flavones |
| CN101797344A (en) * | 2010-04-16 | 2010-08-11 | 南京中医药大学 | Method for preparing refined total flavonoids in herba lophatheri |
-
2012
- 2012-07-03 CN CN201210226041.3A patent/CN102698116B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766274A (en) * | 2010-01-05 | 2010-07-07 | 杭州尤美特科技有限公司 | Antioxidant functional food composition containing bamboo-leaves flavones |
| CN101797344A (en) * | 2010-04-16 | 2010-08-11 | 南京中医药大学 | Method for preparing refined total flavonoids in herba lophatheri |
Non-Patent Citations (1)
| Title |
|---|
| 丁灵英: "神奇的竹叶黄酮", 《知识经济》, no. 01, 31 December 2007 (2007-12-31), pages 20 - 22 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287499A (en) * | 2015-10-09 | 2016-02-03 | 成都普瑞法科技开发有限公司 | Natural pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular diseases and application of pharmaceutical composition |
| CN105738553A (en) * | 2016-02-05 | 2016-07-06 | 四川德成动物保健品有限公司 | Thin-layer chromatography detection method for lophatherum gracile in scourge-clearing toxin-vanquishing powder |
| CN112587621A (en) * | 2020-12-18 | 2021-04-02 | 江西中医药大学 | Medicine for resisting myocardial ischemic diseases and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102698116B (en) | 2014-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baliga | Review of the phytochemical, pharmacological and toxicological properties of Alstonia scholaris Linn. R. Br (Saptaparna) | |
| CN102302555A (en) | Chinese medicinal extract for treating urarthritis, as well as preparation method and application thereof | |
| CN101849957B (en) | Application of Dendrobium officinale polysaccharide in preparation of medicine for preventing and treating hypertension and apoplexy | |
| CN101612316B (en) | Application of dendrobium officinale aqueous extract in preparing medicine for preventing and treating hypertension and apoplexy | |
| CN104431064A (en) | Blood glucose-lowering tea and preparation method thereof | |
| CN104522639A (en) | Anti-intoxication, alcohol-expelling and liver-protection preparation and preparation process thereof | |
| CN108210748A (en) | A kind of stem of noble dendrobium composition of resisting alcoholic hepatic injury and its preparation method and application | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN102698116B (en) | Application of lophatherum gracile total flavonoids in preparation of medicine and functional food for preventing and treating myocardial ischemia disease | |
| CN104224885A (en) | Traditional Chinese medicine composition for relieving physical fatigue | |
| WO2008061447A1 (en) | A medicine for treating eczema and process of ointment thereof | |
| CN104435034A (en) | PNS (panax notoginseng saponins) and preparation method thereof | |
| CN103860611A (en) | Crape myrtle extract as well as extraction method and application thereof | |
| CN104887835A (en) | Healthcare product prepared through natural plants | |
| CN104173451A (en) | Application of natural pharmaceutical composition in blood glucose-reducing drugs and health food | |
| WO2017121333A1 (en) | Use of cistanche tubulosa extract and isoacteoside in protection of muscles | |
| CN101856466A (en) | Medicine preventing and treating hypertension and stroke and being prepared by dendrobium officinale flower and method | |
| CN102861114A (en) | Kiwi fruit extract and extraction method and application thereof | |
| CN107184671B (en) | Analgesic formula and extraction method and test method thereof | |
| JP2006516542A5 (en) | ||
| CN103948767A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, as well as preparation method and application thereof | |
| CN104127545B (en) | New application of murraya tetramera huang and extract thereof in preparation of medicines | |
| CN102293816B (en) | Production method of rheumatism dripping pill | |
| JPS60260520A (en) | Drug composition | |
| CN105663224A (en) | Composition for treating cardiovascular and cerebrovascular diseases and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |